IOVANCE BIOTHERAPEUTICS INC's ticker is IOVA and the CUSIP is 462260100. A total of 247 filers reported holding IOVANCE BIOTHERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is 0.25 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $17,124,553 | -31.2% | 3,763,638 | +6.5% | 0.00% | -40.0% |
| Q2 2023 | $24,888,280 | +3.6% | 3,535,267 | -10.1% | 0.01% | 0.0% |
| Q1 2023 | $24,030,532 | +3.2% | 3,932,984 | +8.0% | 0.01% | 0.0% |
| Q4 2022 | $23,279,185 | -18.9% | 3,643,065 | +21.6% | 0.01% | -28.6% |
| Q3 2022 | $28,692,000 | +33.1% | 2,994,979 | +53.4% | 0.01% | +40.0% |
| Q2 2022 | $21,554,000 | +116.0% | 1,952,346 | +225.7% | 0.01% | +150.0% |
| Q1 2022 | $9,979,000 | -65.0% | 599,371 | -59.9% | 0.00% | -60.0% |
| Q4 2021 | $28,525,000 | -7.8% | 1,494,204 | +19.1% | 0.01% | -28.6% |
| Q3 2021 | $30,951,000 | -30.9% | 1,255,100 | -27.1% | 0.01% | -30.0% |
| Q2 2021 | $44,822,000 | -26.2% | 1,722,578 | -10.2% | 0.01% | -33.3% |
| Q1 2021 | $60,709,000 | +75.4% | 1,917,509 | +157.1% | 0.02% | +66.7% |
| Q4 2020 | $34,604,000 | +28.3% | 745,770 | -9.0% | 0.01% | +12.5% |
| Q3 2020 | $26,967,000 | -31.4% | 819,151 | -42.8% | 0.01% | -33.3% |
| Q2 2020 | $39,290,000 | +16.3% | 1,431,325 | +26.8% | 0.01% | 0.0% |
| Q1 2020 | $33,785,000 | -0.8% | 1,128,608 | -8.2% | 0.01% | +50.0% |
| Q4 2019 | $34,044,000 | +78.5% | 1,229,954 | +17.4% | 0.01% | +33.3% |
| Q3 2019 | $19,070,000 | +35.6% | 1,047,792 | +82.7% | 0.01% | +50.0% |
| Q2 2019 | $14,060,000 | +238.1% | 573,378 | +31.1% | 0.00% | +300.0% |
| Q1 2019 | $4,158,000 | -32.2% | 437,263 | -36.9% | 0.00% | -50.0% |
| Q4 2018 | $6,136,000 | +183.3% | 693,301 | +260.1% | 0.00% | +100.0% |
| Q3 2018 | $2,166,000 | +99.1% | 192,536 | +126.4% | 0.00% | – |
| Q2 2018 | $1,088,000 | -32.1% | 85,037 | -10.3% | 0.00% | – |
| Q1 2018 | $1,602,000 | +215.4% | 94,793 | +49.5% | 0.00% | – |
| Q4 2017 | $508,000 | -70.6% | 63,414 | -71.5% | 0.00% | – |
| Q3 2017 | $1,727,000 | +9.7% | 222,784 | +4.0% | 0.00% | – |
| Q2 2017 | $1,575,000 | – | 214,211 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Perceptive Advisors | 12,201,261 | $203,150,000 | 4.07% |
| Paradigm Biocapital Advisors LP | 907,428 | $15,109,000 | 4.00% |
| Avoro Capital Advisors LLC | 9,125,000 | $151,931,000 | 2.77% |
| Logos Global Management LP | 1,000,000 | $16,650,000 | 2.16% |
| Avidity Partners Management LP | 6,043,219 | $100,620,000 | 2.10% |
| Orbimed Advisors | 6,633,006 | $110,440,000 | 1.79% |
| Parametrica Management Ltd | 134,679 | $2,240,000 | 1.66% |
| Boxer Capital, LLC | 1,935,133 | $32,220,000 | 1.66% |
| Fairmount Funds Management LLC | 389,588 | $6,487,000 | 1.53% |
| Long Focus Capital Management, LLC | 705,000 | $11,738,000 | 1.51% |